Indeed, a recent study from the GIMEMA Working Party on CML reported that the early detection of BCR/ABL mutations in CML chronic phase patients is associated with a greater likelihood of disease progression (Soverini et al, 2005). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.